Aat Costech Co., Ltd.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 2 name spellings.
3
Ending by 2030
Jan 2029
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 2 fees due Jun 1 to 17, 2027 · next Jun 1
- 1 fee due Nov 12, 2027The maintenance fee for Composition for preventing, alleviating or treating muscle diseases or improving muscular function (US 10,646,498) comes due Nov 12, 2027. Unpaid by May 12, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Showing 1 to 10 of 10
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,435,957 | Use of lignan compound for anti-wrinkle treatment In force · From the USPTO record | In force | From the USPTO record | |
| US 8,653,143 | Use of panduratin derivative or Boesenbergia pandurata extract In force · From the USPTO record | In force | From the USPTO record | |
| US 8,969,408 | Use of lignan-type compounds or extract of nutmeg or aril of nutmeg comprising the same In force · From the USPTO record | In force | From the USPTO record | |
| US 9,452,193 | Use of panduratin derivatives or an extract of Boesenbergia pandurata for enhancing muscle mass growth, fighting fatigue, and enhancing exercise performance In force · From the USPTO record | In force | From the USPTO record | |
| US 9,198,880 | Use of panduratin derivatives or an extract of Boesenbergia pandurata for promoting muscle mass growth, fighting fatigue, and enhancing exercise performance capability In force · From the USPTO record | In force | From the USPTO record | |
| US 9,511,048 | Use of Flavone Compound for Prevention or Treatment of Obesity In force · High confidence | In force | High confidence | |
| US 9,669,066 | Use of Kaempferia Parviflora Wall. Ex. Baker Extracts or Flavone Compound for Preventing or Treating Muscle Diseases, or Improving Muscle Function In force · High confidence | In force | High confidence | |
| US 10,188,690 | Use of Kaempferia parviflora wall. ex. baker extracts or flavone compound for preventing or treating muscle diseases, or improving muscle function In force · From the USPTO record | In force | From the USPTO record | |
| US 10,507,224 | Composition including kirenol or siegesbeckia herba extract for muscle function improvement or exercise ability enhancement In force · From the USPTO record | In force | From the USPTO record | |
| US 10,646,498 | Composition for preventing, alleviating or treating muscle diseases or improving muscular function In force · From the USPTO record | In force | From the USPTO record |
Also on record, not counted in the 10: 1 lapsed for an unpaid fee · 1 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
1 abandoned · 2 no status recorded